Apply for Gilenya (Fingolimod) Copay Assistance Now

Gilenya (Fingolimod) is an immunosuppressant. It works by keeping immune cells trapped in your lymph nodes so they can’t reach the central nervous system (brain and spinal cord).

Gilenya is used to treat relapsing multiple sclerosis (MS) in adults, and children and adolescents aged 10 years and older.

Gilenya will not cure MS, it will only decrease the frequency of relapse symptoms.

Another brand name is Tascenso ODT, which stands for “Orally Disintegrating Tablet.” This refers to the fact that this version of Fingolimod melts on the tongue and does not need to be swallowed.

In adults and pediatric patients 10 years of age and older weighing more than 40 kg, the recommended dosage of Gilenya is 0.5 mg orally once-daily.

In pediatric patients 10 years of age and older weighing less than or equal to 40 kg, the recommended dosage of Gilenya is 0.25 mg orally once daily.

Fingolimod doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit.

Common Side Effects

These may occur in more than 1 in 10 patients:

• Headache

• Flu

• Diarrhea

• Back pain

• Cough

• Increased liver enzymes (ALT, AST)

• Abdominal pain

• Fatigue

• Depression

• Sinusitis

• Pain in extremities

• Dizziness

Infections (Due to Immune Suppression)

• Upper respiratory tract infections (cold, sinusitis)

• Bronchitis

• Herpes virus infections (cold sores, shingles)

• Fungal infections

• Urinary tract infections

• Pneumonia (rare but serious)

Note: Fingolimod increases the risk of serious infections, including progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection.

Cardiac Side Effects

Especially around the time of first dose:

• Bradycardia (slow heart rate)

• Atrioventricular (AV) block

• Palpitations

• Hypotension

• Fainting or dizziness due to slowed heart rate

Monitoring required: First-dose observation with ECG monitoring for at least 6 hours is recommended.

Eye-Related Side Effects

• Macular edema (swelling of the retina):

  • Blurred vision

  • Shadows or blind spots

  • Decreased visual acuity

  • Most likely to occur within 3-4 months of treatment

Risk increases in patients with diabetes or history of uveitis. An eye exam is recommended before starting and again after 3–4 months.

Liver and Blood-Related Side Effects

• Elevated liver enzymes (ALT, AST, GGT, bilirubin)

• Hepatotoxicity

• Lymphopenia (low lymphocyte count)

• Leukopenia (low white blood cell count)

• Thrombocytopenia (low platelet count)

Neurologic and Psychiatric Side Effects

• Headache

• Migraine

• Dizziness

• Depression

• Anxiety

• Insomnia

• Seizures (rare but reported)

• Suicidal thoughts or behavior (rare, monitor in those with history of depression)

Pulmonary Side Effects

• Shortness of breath (dyspnea)

• Cough

• Decrease in lung function (reduced FEV1)

• Rare: interstitial lung disease

Skin and Hair Side Effects

• Rash

• Eczema

• Alopecia (hair thinning or loss)

• Pruritus (itching)

Rare but Serious Adverse Reactions

• Progressive multifocal leukoencephalopathy (PML) – life-threatening brain infection

• Posterior reversible encephalopathy syndrome (PRES) – a rare neurological disorder

• Severe liver injury

• Melanoma – increased risk of skin cancer

• Basal cell carcinoma – monitor skin regularly

• Hemophagocytic lymphohistiocytosis (HLH) – a life-threatening immune overactivation syndrome

• Rebound MS disease activity after stopping fingolimod—can be severe or life-threatening

Reproductive Concerns

• Pregnancy Category X: Teratogenic in animals—contraindicated in pregnancy

• Women of childbearing potential should use effective contraception during and for 2 months after stopping treatment

While it is not possible to determine what your copay cost or cash price will be for Gilenya or its generic counterpart Fingolimod, calling our pharmacy team or filling out the form above will be the best way to get the fastest answers.

We believe that high deductibles and copays shouldn’t prevent anyone from receiving the medications they need. That’s why at QuickRx, we offer a Movement Disorder Copay Assistance Program that includes Gilenya Copay Assistance.

This is designed to help patients reduce their copays and out-of-pocket costs for their medication. Our program partners with various foundations and manufacturer assistance programs to help make a patient’s medication affordable.

Here are the ways to apply for the Gilenya (Fingolimod) Copay Assistance program:

• • You can call us at (917) 830-2525 
  • You can also fill out our Contact Form above and someone will call you back within 1-2 business days.

Gilenya is an immunosuppressant. It works by keeping immune cells trapped in your lymph nodes so they can’t reach the central nervous system (brain and spinal cord).

Gilenya and its generic Fingolimod are both produced as a capsule.

Gilenya (Fingolimod) should be taken orally (by mouth) with water.

Call your doctor for instructions. If you miss 1 or more doses, you may need to take your next dose under medical observation in a medical setting.

Gilenya (Fingolimod) is a medication prescribed for Multiple Sclerosis. It works by reducing the number of certain immune cells in the body that can attack the nervous system in MS. By modulating the immune response, Gilenya helps reduce the frequency of MS relapses and slows down the progression of the disease.

Gilenya is approved for the treatment of relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS) in some countries. It is not indicated for primary progressive MS.